HeimSHTDF • OTCMKTS
add
Sinopharm Group Co Ltd
Við síðustu lokun
1,97 $
Árabil
1,97 $ - 2,95 $
Markaðsvirði
63,04 ma. HKD
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
HKG
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CNY) | jún. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 147,46 ma. | -5,13% |
Rekstrarkostnaður | 6,38 ma. | -2,07% |
Nettótekjur | 2,28 ma. | -9,16% |
Hagnaðarhlutfall | 1,55 | -4,32% |
Hagnaður á hvern hlut | — | — |
EBITDA | 5,57 ma. | -12,42% |
Virkt skatthlutfall | 21,74% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CNY) | jún. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 43,33 ma. | 26,05% |
Heildareignir | 429,58 ma. | 2,85% |
Heildarskuldir | 307,15 ma. | 0,84% |
Eigið fé alls | 122,43 ma. | — |
Útistandandi hlutabréf | 3,12 ma. | — |
Eiginfjárgengi | 0,08 | — |
Arðsemi eigna | 2,96% | — |
Ávöxtun eigin fjár | 5,84% | — |
Peningaflæði
Breyting á handbæru fé
| (CNY) | jún. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 2,28 ma. | -9,16% |
Handbært fé frá rekstri | 6,49 ma. | 346,39% |
Reiðufé frá fjárfestingum | -1,29 ma. | -269,35% |
Reiðufé frá fjármögnun | -602,70 m. | -425,16% |
Breyting á handbæru fé | 4,59 ma. | 374,61% |
Frjálst peningaflæði | -22,56 ma. | 29,73% |
Um
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Stofnsett
2003
Vefsvæði
Starfsfólk
113.635
